Predictive Analysis of Dementia

logo mammut
¹ÙÀÌ¿À ¸¶Ä¿ ±â¹Ý(ºÐÀÚ+¸é¿ª)
Çѱ¹Çü ÅëÇÕÄ¡¸ÅÁ¶±âÁø´Ü±â¼ú ¿¬±¸

°æµµÀÎÁöÀå¾Ö(MCI : Mild Cognitive Impairment)¿Í ¹«Áõ»ó ³úÁ¹Áß(SBI : Silent Brain Infraction)À» ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý Áø´Ü±â¼ú·Î ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡¸Å(Alzheimer's Disease Dementia) ¹× Ç÷°ü¼º Ä¡¸Å(Vascular dementia) ÅëÇÕ Áø´Ü¼­ºñ½º ¸ðµ¨À» ¿¬±¸ °³¹ß ÇÏ°í ÀÖ½À´Ï´Ù.
Ä¡¸ÅÁ¶±â°Ë»çÀÇ Æä·¯´ÙÀÓÀ» ¹Ù²Ü ¼ö ÀÖ´Â ±âȹ(¼³°è)µÈ ¹ÙÀÌ¿À ±â¹Ý °Ë»ç±â¹ýÀ¸·Î Çѱ¹Çü ¿ä±¸¿¡ ±ÙÁ¢ÇÑ È¿°úÀûÀÎ Á¶±â Áø´ÜÀÌ ½±°í ºü¸£°Ô Á¤ÀÇ µË´Ï´Ù.
KGICÀÇ 'Çѱ¹Çü ÅëÇÕÄ¡¸ÅÁ¶±â°Ë»ç ÇÁ·ÎÁ§Æ®'´Â ºñÁî´Ï½º ´ÜÀ§ÀÇ ¿¬±¸ °³¹ßÀ» ÇÏ´Â ÁøÁ¤ÇÑ Àü¹®°¡ ÀÔ´Ï´Ù.

responsive priview
  • MCI-K¢â
  • HDLÀÇ ÁÖ¿ä ´Ü¹éÁúÀÌ°í A¥â¿Í °áÇÕÇÏ¿© ³ú/CSF ·ÎºÎÅÍ Ç÷¾×À¸·Î A¥â¸¦ À̵¿ÇÏ´Â ¿ªÇÒ ¼öÇà, ½Å°æ ¼¼Æ÷ÀÇ ¿°Áõ ¿ÏÈ­ ¿ªÇÒÇÏ´Â ApoA1¿Í A¥â¿Í °áÇÕ A¥âÀÌ aggregationµÇ´Â °ÍÀ» ¹æ¾îÇÏ¿© A¥âÀÇ neurotoxicity ¾ïÁ¦ ±â´É ´Ü¹éÁú, AD ȯÀÚ¿¡¼­ ³·Àº TTR ³óµµ°¡ À¯ÀÇÀûÀ¸·Î º¸°íµÇ°í ÀÖ´Â TTR, ¸é¿ª¿¡ °ü¿©, Àü¿°Áõ¼º ¹ÝÀÀÀÚ ÃàÀûµÇ´Â A¥â¸¦ ½Å°æ ±³¼¼Æ÷¸¦ È°¼ºÇÏ¿© Æ÷½ÄÇÏ¿© Á¦°ÅÇϰųª, Plaque Çü¼º ¾ïÁ¦(C3³óµµ ÀúÇÏ=A¥â ³úÃàÀû°ú ½Å°æ¼¼Æ÷ÀÇ ¿°ÁõÀÇ ÁöÇ¥)ÇÏ´Â C3 º¸Ã¼´Ü¹éÁúÀÇ ¸¶Ä¿¸¦ ÀÌ¿ëÇÑ Çѱ¹Çü MCI ºÐ¼®±â¹ý¿¬±¸.
  • SBI-K¢â
  • ¾Ëµ¥È÷µåÀÇ ÀÏÁ¾ÀÇ À¯Çع°Áú·Î ÀÎü ³»¿¡¼­ ÁöÁú°ú»êÈ­ »ý¼ºÇÏ°í µ¿¸Æ °æÈ­Áõ ½ÅºÎÀü, ³úÁ¹Áß¿¡ ´ëÇÑ ¸¶Ä¿·Î À¯¿ë¼ºÀÌ º¸°íµÇ°í ÀÖ´Â Acrolein°ú ¿°Áõ¼º »çÀÌÅäÄ«ÀÎÀÇ »ý»êÀ» À¯µµÇϸç, IL-6 ¹× IL-8ÀÇ »ý»êÀ» À¯µµÇÏ¿© ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß¿¡¼­ °ü·ÃµÇ¸ç, Áõ»óÀÇ ÁøÇà¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â IL-6°ú Ç÷Àå¿¡¼­ ¹ß°ßµÇ´Â ÆæŸ¸Ó ´Ü¹éÁú·Î CRPÀÇ ³óµµÀÇ Áõ°¡´Â ´ë½Ä¼¼Æ÷¿Í T¼¼Æ÷¿¡¼­ IL-6ÀÌ ºÐºñµÊ¿¡ µû¶ó Ç÷Áß ³óµµ°¡ Áõ°¡ÇÏ¿© ³ú¼Õ»ó Á¤µµ¿Í Ç÷°ü ¼Õ»óÀÇ Á¤µµ¸¦ ¿¹ÃøÇÏ´Â µ¥ Áß¿ëÇÑ CRP¸¶Ä¿¸¦ ÀÌ¿ëÇÑ Çѱ¹Çü SBI ºÐ¼®±â¹ý¿¬±¸.
2021³â MCI-K¢â ºÎ»ê´ëÇб³º´¿ø Á¤½Å°ú ÀÓ»ó½ÃÇè ÁøÇà

2021³â MCI-K¢â ÀÎÁ¦´ëÇб³ºÎ»ê¹éº´¿ø ½Å°æ°ú ÀÓ»ó½ÃÇè ÁøÇà

2021³â SBI-K¢â ÀÓ»ó½ÃÇè ÁغñÁß

¾ËÃ÷ÇÏÀ̸ÓÇü °æµµÀÎÁöÀå¾Ö Á¶±âÁø´Ü
MCI-K¢â

NDC¿¡¼­µµ ¾ËÃ÷ÇÏÀ̸ÓÇü Ä¡¸ÅÀÇ º´Å »ý¸®ÀÎ A¥âÀÇ Ä§ÂøÀÌ ÀϺΠÀÖÀ» ¼ö ÀÖ´Â ¸íÈ®ÇÑ ±âÁØÀÇ NDC ±ÔÁ¤ÇÏ°í ºñ ¾ËÃ÷ÇÏÀ̸ÓÇü(A¥â-PET(-)) °æµµÀÎÁöÀå¾Ö ´ëÁ¶±ºÀ» Æ÷ÇÔÇÑ Çѱ¹Çü ¾ËÃ÷ÇÏÀ̸ÓÇü °æµµÀÎÁöÀå¾Ö ƯÀÌÀû Áø´Ü±â¼ú ¿¬±¸ ¹× ÀÓ»óÁøÇà ÁßÀÔ´Ï´Ù.

Biomarker
Apolipoprotein A-I

Commercial kit (Sekisui)¸¦ »ç¿ëÇÏ¿© ȥŹ¸é¿ª¹ý (Turbidimetric immunoassay, TIA)À¸·Î ÀÚµ¿È­Àåºñ (Hitach, AUTOMATIC ANALYZER MODEL 7020)¸¦ »ç¿ëÇÏ¿© ÃøÁ¤.

Biomarker
Transthyretin

Commercial kit (Nittobo)¸¦ »ç¿ëÇÏ¿© ȥŹ¸é¿ª¹ý (Turbidimetric immunoassay, TIA)À¸·Î ÀÚµ¿È­Àåºñ (Hitach, AUTOMATIC ANALYZER MODEL 7020)¸¦ »ç¿ëÇÏ¿© ÃøÁ¤.

Biomarker
C3

nC3 Ç×ü (Capture, Detection)¸¦ MCBI¿¡¼­ Á¦°øÇÏ´Â ELISA (enzyme-linked immunosorbent assay) ¹æ¹ýÀ¸·Î ÃøÁ¤.

Ç÷°ü¼ºÄ¡¸ÅÇü ¹«Áõ»ó³úÁ¹Áß Á¶±âÁø´Ü
SBI-K¢â

IL6, hs-CRP, Acro ´Ü¹éÁú ¸¶Ä¿¸¦ Evaluated using ROC (Receiver operating characteristic) curve, NEUROSIM/L software (Including factor_Age)ÀÇ ÃøÁ¤°ªÀ» ºÐ¼®ÇÏ¿© ¹«Áõ»ó³úÁ¹ÁßÀÇ Æ¯ÀÌÀû Áø´Ü±â¼ú ¿¬±¸ ¹× ÀÓ»óÁøÇà ÁßÀÔ´Ï´Ù.

Biomarker
Acrolein

Polyamine oxidase (PAO)
PolyamineÀº cell growth ¹× viability¿¡ Áß¿äÇÑ ¿ªÇÒ
¼¼Æ÷°¡ ¼Õ»óÀ» ÀÔÀ¸¸é, polyamineÀº toxic compound (acrolein) °ú H2O2·Î ºÐÇØ
ÁÖ¿ä È°¼º»ê¼Ò ROS º¸´Ù µ¶¼ºÀÌ °­ÇÔ
Well-correlated with the severity (½ÅºÎÀü, ³úÁ¹Áõ)
³úÁ¹Áõ¿¡ ´ëÇÑ ¹Ù¾Æ¿À¸¶Ä¿·Î À¯¿ë¼ºÀÌ º¸°íµÊ

Biomarker
IL-6 (Interleukine 6)

Acts as pro-inflammatory cytokine
Capable of crossing the blood-brain barrier

Biomarker
CRP (C-reactive protein)

°£¿¡¼­ »ý¼ºµÇ¾î Ç÷·ù·Î ºÐºñ
¿°Áõ°ú °¨¿°, ½É±Ù°æ»ö, ¼ö¼ú ÈÄ ¹× ¿Ü »ó½Ã¿¡ Áõ°¡
±Þ¼º±â ¹ÝÀÀ¹°ÁúÀ̶ó ºÒ¸®¿ì´Â ¿©·¯ ´Ü¹éÁú Áß Çϳª
¿©·¯ °¨¿°Áúȯ ¹× ÀÚ°¡¸é¿ªÁúȯ°ú °ü·ÃµÈ ¿°ÁõÀÇ º¯È­¸¦ °¨½Ã

Contact to us

KGIC°¡ Á¦°øÇÏ´Â °¢Á¾ ºÐÀÚÁø´Ü¼­ºñ½º ¹× R&D°ü·Ã ºñÁî´Ï½º ÆÄÆ®³Ê °ü·Ã ¹®ÀÇ»çÇ×À̳ª ÀÇ°ß»çÇ× ÀÖÀ¸½Ã¸é
Contact us¸¦ ÀÌ¿ëÇØ Áֽøé ÃÖ¼±À» ´ÙÇØ ´äº¯ µå¸®°Ú½À´Ï´Ù.

Partner Inquiry

News & Media

Á¦Ç° ¹× ¼­ºñ½º ¼Ò½Ä, º¸µµÀÚ·á ¹× È«º¸ÀÚ·á
IR/PR µî KGIC ¼Ò½ÄÀ» ÀüÇص帳´Ï´Ù.

Detail view